With an unchanged $10 price target, H.C. Wainwright maintained its Buy rating on Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on May 29.
Sangamo Therapeutics, Inc. is closing in on important milestones, such as the crucial Phase 2 data release from the Fabry disease-focused STAAR study, which should occur by the end of 2025’s second quarter. A favorable result from this experiment could greatly lower investment risk, according to analysts at H.C. Wainwright. This optimism is predicated on the possibility of submitting a Biologics License Application (BLA) in the first quarter of 2026 and prospectively approving what may be the first gene treatment for this illness in the second half of the same year.
Additionally, the company’s MINT platform presented new preclinical findings at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy. Analysts believe that Sangamo’s pipeline and platform execution are well-positioned to achieve significant growth, especially while talks for new partnerships continue and recent financial moves stretch the company’s operational funding beyond the later part of the third quarter of 2025.
Read More: 10 Best Stocks to Buy According to the Bill & Melinda Gates Foundation Trust and 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies.
